Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kiniksa Pharmaceuticals International (KNSA) Change in Account Payables (2021 - 2025)

Kiniksa Pharmaceuticals International (KNSA) has disclosed Change in Account Payables for 5 consecutive years, with -$4.1 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Change in Account Payables rose 34.4% year-over-year to -$4.1 million, compared with a TTM value of $142000.0 through Dec 2025, up 102.25%, and an annual FY2025 reading of $142000.0, up 102.25% over the prior year.
  • Change in Account Payables was -$4.1 million for Q4 2025 at Kiniksa Pharmaceuticals International, down from -$2.7 million in the prior quarter.
  • Across five years, Change in Account Payables topped out at $7.2 million in Q4 2023 and bottomed at -$6.5 million in Q1 2023.
  • Average Change in Account Payables over 5 years is $79000.0, with a median of $67000.0 recorded in 2021.
  • The sharpest move saw Change in Account Payables surged 2472.0% in 2022, then tumbled 529.57% in 2023.
  • Year by year, Change in Account Payables stood at $250000.0 in 2021, then soared by 2472.0% to $6.4 million in 2022, then grew by 12.5% to $7.2 million in 2023, then crashed by 186.87% to -$6.3 million in 2024, then soared by 34.4% to -$4.1 million in 2025.
  • Business Quant data shows Change in Account Payables for KNSA at -$4.1 million in Q4 2025, -$2.7 million in Q3 2025, and $6.9 million in Q2 2025.